



**Contact:**

Christine Slocumb  
Principal, The onQuest Group  
cslocumb@on-quest.com  
206-799-1949

**For immediate release**

## **Kurve Technology invited to speak at international nasal drug delivery conference**

***Innovative nasal drug delivery method will be presented to pharmaceutical and device experts***

***BOTHELL, WA – March 21, 2005:*** Kurve Technology, Inc. will present a paper on Controlled Particle Dispersion™ (CPD) —its innovative nasal drug delivery technology — on April 7 at the Management Forum's Annual International Conference on Nasal Drug Delivery in London.

Kurve President and COO William DeGrootd will discuss and demonstrate Kurve's groundbreaking method of effective intranasal drug delivery that enables patients to quickly and painlessly administer drugs. DeGrootd also will demonstrate ViaNase,™ an advanced nasal drug delivery system that can optimally saturate the entire nasal cavity and deliver drugs to the paranasal sinuses.

Using the principal of vortical flow, CPD effectively disrupts inherent nasal cavity airflows to deliver compounds to the entire nasal cavity. CPD optimizes droplet size and trajectory to saturate the nasal cavity, lengthen compound residence time, and minimize deposition to the lungs. Early indications from clinical investigation show that the average area of intranasal deposition was as much as 300 percent greater for ViaNase compared to nasal spray bottles. In fact, in most cases, up to 90 percent of formulations delivered by spray bottles or nebulizers simply fail to reach their intended target.

DeGrootd's presentation will underscore that if preliminary clinical research findings bear true, CPD could dramatically increase efficacy for patients dependent on drug therapy for their quality of life.

***CPD is cover story in Drug Delivery Technology***

Kurve's CPD is the subject of an extensive article that appears in the March issue of *Drug Delivery Technology*, a leading publication in the field. Titled "Controlled Particle Dispersion™: Applying Vortical Flow to Optimize Nasal Drug Deposition," the article offers a detailed explanation of CPD's effectiveness and potential.

Information on International Conference on Nasal Drug Delivery can be found at [www.management-forum.co.uk](http://www.management-forum.co.uk) .

**-30-**

**About Kurve Technology, Inc.**

Founded in 2001, **Kurve Technology, Inc.** designs and develops nasal drug delivery systems. Kurve's Controlled Particle Dispersion (CPD)™ technology intranasally delivers compounds with greater efficacy and efficiency than traditional spray bottles, inhalers or nebulizers. Clinical trials are underway at Oregon Health Sciences University (Portland) and other leading medical institutions. [www.kurve-tech.com](http://www.kurve-tech.com).